CEL-SCI Is Granted a New European Patent on Its Phase 3 Investigational Cancer Immunotherapy Multikine
CEL-SCI Corporation announces that it has been granted a European patent on Multikine (Leukocyte Interleukin, Injection), its investigational Phase 3 cancer immunotherapy. The patent, number EP 1 753 452 B, is entitled: A METHOD FOR ALTERING THE CD4/CD8 RATIO AND THE MONONUCLEAR CELLULAR INFILTRATE INTO A TUMOR.
View full press release